FrancophonIA/ELRC3.0 huggingface dataset:
English: HPDE bottles carton and HPDE bottles of 60 tablets
Slovenian: PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI Škatla za steklenice iz HPDE in steklenice iz HPDE, ki vsebujejo 60 tablet
English: Urinary tract infection
Slovenian: Bolezni sečil okužba sečil
English: Zebinix 800 mg tablets Eslicarbazepine acetate
Slovenian: Zebinix 800 mg tablete eslikarbazepinacetat
English: White oblong tablets, engraved ‘ESL 800'on one side and scored on the other side, with a length of 19 mm.
Slovenian: Bele, podolgovate tablete z vtisnjenim napisom ‘ESL 800' na eni strani in zarezo na drugi strani, dolžine 19 mm. Tableta se lahko deli na enake odmerke.
English: The tablets have ‘ESL 200'engraved on one side and are scored on the other side, with a length of 11 mm.
Slovenian: Tablete imajo vtisnjen napis ‘ESL 200' na eni strani in zarezo na drugi, dolžine 11 mm. Tableta se lahko deli na enake odmerke.
English: Zebinix 400 mg tablets
Slovenian: Zebinix 400 mg tablete
English: Severe cutaneous adverse reactions (SCARS) including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported in post-marketing experience with Zebinix treatment.
Slovenian: V obdobju trženja so pri zdravljenju z zdravilom Zebinix poročali o hudih kožnih neželenih reakcijah, vključno s Stevens-Johnsonovim sindromom (SJS)/toksično epidermalno nekrolizo (TEN) ter reakcijo na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS), ki so lahko življenjsko ogrožajoče ali smrtne.
English: Each tablet contains 200 mg of eslicarbazepine acetate.
Slovenian: Ena tableta vsebuje 200 mg eslikarbazepinacetata.
English: Zebinix 600 mg tablets
Slovenian: Zebinix 600 mg tablete
English: Zebinix 800 mg tablets are white and oblong.
Slovenian: Tablete Zebinix 800 mg so bele in podolgovate.
English: • Weight loss;
Slovenian: • izguba telesne mase,
English: • Seizures;
Slovenian: • zaprtost,
English: Outer carton / bottle
Slovenian: PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI Škatla/steklenica
English: Thus, interactions can arise when co-administering high doses of eslicarbazepine acetate with medicinal products that are mainly metabolised by CYP2C19 (e.g. Phenytoin).
Slovenian: Eslikarbazepin zavira delovanje CYP2C19, zato lahko pride do interakcij pri sočasni uporabi velikih odmerkov eslikarbazepinacetata in zdravil, ki jih večinoma presnavlja
English: Zebinix 600 mg tablets are white and oblong.
Slovenian: Tablete Zebinix 600 mg so bele in podolgovate.
English: • Liver problems;
Slovenian: • težave z jetri,
English: • Feeling generally weak, unwell or having chills;
Slovenian: • okužba sečil, • splošna šibkost, slabo počutje ali mrzlica,
English: Zebinix 200 mg tablets Eslicarbazepine acetate
Slovenian: Zebinix 200 mg tablete eslikarbazepinacetat
English: Zebinix 200 mg tablets are white and oblong.
Slovenian: Tablete Zebinix 200 mg so bele in podolgovate.
English: Zebinix 400 mg tablets Eslicarbazepine acetate
Slovenian: Zebinix 400 mg tablete eslikarbazepinacetat
English: Zebinix 600 mg tablets Eslicarbazepine acetate
Slovenian: Zebinix 600 mg tablete eslikarbazepinacetat
English: Co-administration of eslicarbazepine acetate 1,200 mg once daily with warfarin showed a small (23%), but statistically significant decrease in exposure to S-warfarin.
Slovenian: Varfarin Pri sočasni uporabi 1.200 mg eslikarbazepinacetata enkrat na dan in varfarina so opazili majhno
English: The tablets have ‘ESL 400'engraved on one side and are scored on the other side, with a diameter of 11 mm.
Slovenian: Na eni strani je vtisnjen napis ‘ESL 400', na drugi pa je zareza, premera 11 mm.
English: • Hearing difficulty;
Slovenian: • težave s sluhom,
English: There was an average decrease of 36-39% in systemic exposure in healthy subjects when co-administered with eslicarbazepine acetate 1,200 mg once daily.
Slovenian: Pri sočasni uporabi z eslikarbazepinacetatom v odmerku 1.200 mg enkrat dnevno je prišlo do povprečnega znižanja sistemske izpostavljenosti za 36-39 % pri zdravih preskušancih.
English: • Having falls;
Slovenian: • padci,
English: Serious and potentially life-threatening skin reactions including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in post-marketing experience in patients treated with Zebinix.
Slovenian: V obdobju trženja so pri bolnikih, ki so se zdravili z zdravilom Zebinix, poročali o hudih kožnih neželenih reakcijah, vključno s Stevens-Johnsonovim sindromom/toksično epidermalno nekrolizo ter reakcijo na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS), ki so lahko tudi življenjsko ogrožajoče.
English: A.
Slovenian: SŠ:
English: Eslicarbazepine acetate
Slovenian: Eslikarbazepinacetat so preizkusili pri odmerkih
English: What you need to know before you take Zebinix 3.
Slovenian: Kaj je zdravilo Zebinix in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Zebinix Kako jemati zdravilo Zebinix
English: Annex B (variation to centrally authorised medicinal products)
Slovenian: ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET Z ZDRAVILOM
English: Thrombocytopenia, leukopenia
Slovenian: parestezija, migrena
English: • Shaking;
Slovenian: • srbenje,
English: D.
Slovenian: dela).
English: Flavour Tutti-Frutti artificial (contains maltodextrin, propylene glycol, natural and artificial flavouring, and gum acacia (E414)
Slovenian: FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi ksantanski gumi (E415) makrogol-100 stearat metilparahidroksibenzoat (E218) natrijev saharinat (E954) umetna aroma tutti frutti (vsebuje maltodekstrin, propilenglikol, naravne in umetne arome in arabski gumi (E414)) prekrivni okus (vsebuje propilenglikol, vodo in naravne ter umetne arome)
English: • with other antiepileptic medicines (adjunctive therapy), in adult, adolescents and children patients above 6 years of age, whoare experiencing seizures that affect one part of the brain (partial seizure).
Slovenian: • monoterapija pri zdravljenju parcialnih epileptičnih napadov s sekundarno generalizacijo ali brez nje pri odraslih z na novo diagnosticirano epilepsijo, • dodatno zdravljenje pri odraslih, mladostnikih in otrocih, starih več kot 6 let, s parcialnimi epileptičnimi napadi s sekundarno generalizacijo ali brez nje.
English: • Constipation;
Slovenian: hladne okončine
English: Pancreatitis
Slovenian: Okskarbazepin
English: Package leaflet: Information for the user Zebinix 50 mg/ml oral suspension
Slovenian: Navodilo za uporabo Zebinix 50 mg peroralna suspenzija eslikarbazepinacetat
English: • with other antiepileptic medicines (adjunctive therapy), in adult, adolescents and children patients above 6 years of age, who are experiencing seizures that affect one part of the brain (partial seizure).
Slovenian: starih več kot 6 let, ki imajo epileptične napade, ki prizadenejo en del možganov (parcialne epileptične napade).
English: Fatigue, gait disturbance, asthenia
Slovenian: apatija, depresija,
English: • Skin rash;
Slovenian: • kožni izpuščaj,
English: ANNEX I NAME, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ANIMAL SPECIES, ROUTES OF ADMINISTRATION, AND MARKETING AUTHORISATION HOLDER
Slovenian: IME, FARMACEVTSKA OBLIKA, JAKOST, CILJNA ŽIVALSKA VRSTA, NAČIN UPORABE ZDRAVILA , IMETNIK(I) DOVOLJENJ(A) ZA PROM
English: The National Competent Authorities of Member States or Reference Member States if applicable, shall ensure that the following condition is fulfilled by the MAH(s):
Slovenian: Pristojni nacionalni organi ene ali več držav članic ali referenčnih držav članic, če je ustrezno, zagotovijo, da imetnik(i) dovoljenj za promet z zdravilom izpolnjuje(jo) naslednji pogoj:
English: Suspension of the marketing authorisations should be lifted when bioequivalence to an EU Reference Medicinal Product has been established based on a bioequivalence study conducted visà-vis the EU Reference Medicinal Product.
Slovenian: Začasen umik dovoljenj za promet z zdravilom se prekliče, ko se ugotovi biološka enakovrednost z referenčnim zdravilom, odobrenim v EU, na podlagi študije biološke enakovrednosti, opravljene glede na referenčno zdravilo, odobreno v EU.
English: Annex III Condition for lifting the suspension of the Marketing Authorisations
Slovenian: Pogoj za preklic začasnega umika dovoljenj za promet z zdravilom
English: The recommended dose is 10 mg per kilogram bodyweight.
Slovenian: Priporočeni odmerek je 10 mg na kilogram telesne mase.
English: Zinplava bezlotoxumab
Slovenian: Zinplava bezlotoksumab
English: What measures are being taken to ensure the safe and effective use of Zinplava?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zinplava?
English: The full EPAR for Zinplava can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zinplava je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Zinplava's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zato zaključil, da so koristi zdravila Zinplava večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: Similar effects have been seen in patients on placebo.
Slovenian: Podobni učinki so bili opaženi pri bolnikih, ki so prejemali placebo.
English: This is a summary of the European public assessment report (EPAR) for Zinplava.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zinplava.
English: A new episode of diarrhoea was defined as 3 or more loose stools in 24 or fewer hours.
Slovenian: Nova epizoda driske je bila opredeljena kot tri- ali večkratna pojavitev redkega blata v 24 urah ali manj.
English: It is given as a single infusion lasting around 1 hour.
Slovenian: Zdravilo se daje enkrat dnevno v obliki enojne infuzije, ki traja približno eno uro.
English: What benefits of Zinplava have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Zinplava izkazalo v študijah?
English: Bezlotoxumab is a monoclonal
Slovenian: Bezlotoksumab je monoklonsko
English: What is Zinplava and what is it used for?
Slovenian: Kaj je zdravilo Zinplava in za kaj se uporablja?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zinplava have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zinplava upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: It is not intended to provide practical advice on how to use Zinplava.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: antibody (a type of protein) that has been designed to attach to these toxins, blocking their action, thereby preventing further damage and diarrhoea from occurring.
Slovenian: protitelo (vrsta beljakovine), zasnovano tako, da se veže na te toksine in zavre njihovo delovanje, s tem pa prepreči nadaljnje poškodbe in drisko.
English: After an initial infection, some dormant forms of the bacteria (spores) may persist in the body and eventually produce further toxins, causing the symptoms to return.
Slovenian: Po začetni okužbi lahko v telesu ostanejo nekatere mirujoče oblike bakterije (spore), ki sčasoma spet proizvedejo toksine, zato se simptomi znova pojavijo.
English: Other information about Zinplava
Slovenian: Druge informacije o zdravilu Zinplava
English: The most common side effects with Zinplava (seen in more than 4 in 100 patients) are nausea (feeling sick), diarrhoea, fever and headache.
Slovenian: Najpogostejši neželeni učinki zdravila Zinplava (opaženi pri več kot 4 bolnikih od 100) so navzeja (slabost), driska, povišana telesna temperatura in glavobol.
English: For more information about treatment with Zinplava, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Zinplava preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: The effect was mainly seen in patients at higher risk of C. difficile infection coming back (such as older patients or those with a weakened immune system).
Slovenian: Učinek je bil v glavnem opažen pri bolnikih z višjim tveganjem za ponovitev okužbe z bakterijo C. difficile (kot so starejši bolniki ali bolniki z oslabljenim imunskim sistemom).
English: What are the risks associated with Zinplava?
Slovenian: Kakšna tveganja so povezana z zdravilom Zinplava?
English: Why is Zinplava approved?
Slovenian: Zakaj je bilo zdravilo Zinplava odobreno?
English: Zinplava has been shown to be effective at preventing recurrence of C. difficile infection, particularly in patients at high risk of the infection coming back (which occurs in about 15 to 35% of cases and is particularly difficult to treat).
Slovenian: Dokazano je bilo, da je zdravilo Zinplava učinkovito pri preprečevanju ponovitve okužbe z bakterijo C. difficile, še posebej pri bolnikih z visokim tveganjem za ponovitev okužbe (do česar pride v približno 15-35 % primerov in kar se še posebej težko zdravi).
English: In the second study, figures were 16% (62 out of 395) for Zinplava and 26% (97 out of 378) for placebo.
Slovenian: V drugi študiji je bilo v skupini, ki je prejemala zdravilo Zinplava, takih bolnikov 16 % (62 od 395), v skupini, ki je prejemala placebo, pa 26 % (97 od 378).
English: For practical information about using Zinplava, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Zinplava naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Zinplava is a medicine used in adults who have infections due to bacteria called Clostridium difficile that cause severe diarrhoea.
Slovenian: Zdravilo Zinplava se uporablja pri odraslih, pri katerih so prisotne okužbe zaradi bakterije, imenovane Clostridium difficile, ki povzroča hudo drisko.
English: In the first study, 17% of patients given Zinplava (67 out of 386) had a new episode of diarrhoea in the 12 weeks after treatment compared with 28% of patients given placebo (109 out of 395).
Slovenian: V prvi študiji je 17 % (67 od 386) bolnikov, zdravljenih z zdravilom Zinplava, v 12 tednih po zdravljenju doživelo novo epizodo driske, pri bolnikih, ki so prejemali placebo, pa je bilo takih bolnikov 28 % (109 od 395).
English: For the full list of all side effects and restrictions with Zinplava, see the package leaflet.
Slovenian: Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Zinplava glejte navodilo za uporabo.
English: Zinplava is available as a concentrate to be made into a solution for infusion (drip) into a vein.
Slovenian: Zdravilo Zinplava je na voljo v obliki koncentrata za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
English: It is used to prevent future episodes of diarrhoea in patients who are taking antibiotics to treat their C. difficile infection and who are at high risk of the infection coming back.
Slovenian: Uporablja se za preprečevanje ponovnih epizod driske pri bolnikih, ki za zdravljenje okužbe z bakterijo C. difficile jemljejo antibiotike in pri katerih obstaja visoko tveganje ponovitve okužbe.
English: Zinplava is generally well tolerated with side effects similar to those observed in patients on placebo.
Slovenian: Bolniki v splošnem dobro prenašajo zdravilo Zinplava, katerega neželeni učinki so podobni tistim, opaženim pri bolnikih, ki so prejemali placebo.
English: C. difficile bacteria produce toxins that damage the lining of the gut causing diarrhoea which may be severe.
Slovenian: Bakterija C. difficile izdeluje toksine, ki lahko poškodujejo sluznico prebavil; to povzroča drisko, ki je lahko huda.
English: How does Zinplava work?
Slovenian: Kako zdravilo Zinplava deluje?
English: How is Zinplava used?
Slovenian: Kako se zdravilo Zinplava uporablja?
English: Zinplava given during antibiotic treatment was shown to be more effective than placebo (a dummy treatment) at preventing a new episode of diarrhoea caused by C. difficile infection in 2 main studies involving a total of 2,655 patients.
Slovenian: V dveh glavnih študijah, ki sta vključevali skupaj 2 655 bolnikov, je bilo dokazano, da je zdravilo Zinplava, dano med zdravljenjem z antibiotiki, pri preprečevanju nove epizode driske, ki jo povzroča okužba z bakterijo C. difficile, učinkovitejše od placeba (zdravila brez zdravilne učinkovine).
English: 21 October 2010
Slovenian: 21. oktober 2010
English: Intrinsa has been authorised since July 2006.
Slovenian: Zdravilo Intrinsa je odobreno od julija 2006.
English: The full European Public Assessment Report for Intrinsa can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila Intrinsa je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The application was withdrawn after ‘day 90'.
Slovenian: Družba je vlogo umaknila po „90.
English: The main measure of effectiveness was based on how frequently the women had ‘satisfying sexual episodes'.
Slovenian: Glavno merilo učinkovitosti je bila pogostnost „zadovoljivih spolnih odnosov“ pri ženskah.
English: This means that the CHMP had evaluated the documentation provided by the company and formulated two lists of questions.
Slovenian: To pomeni, da je CHMP ocenil dokumentacijo, ki jo je predložila družba, in oblikoval dva seznama vprašanj.
English: What is happening with Intrinsa for its existing indication?
Slovenian: Kaj se dogaja z zdravilom Intrinsa za obstoječe indikacije?
English: The letter from the company notifying the Agency of the withdrawal of the application is available under the tab ‘All documents'.
Slovenian: Dopis, s katerim družba agencijo obvešča o umiku vloge, je na voljo pod zavihkom „All documents“ (vsi dokumenti).
English: What consequences does this withdrawal have for patients in clinical trials or compassionate use programmes?
Slovenian: Kakšne so posledice tega umika za bolnike, ki sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila?
English: These women will also be receiving treatment with an oestrogen (a female sex hormone).
Slovenian: Te ženske se zdravijo tudi z estrogenom (ženski spolni hormon).
English: The amount of testosterone in the blood is reduced after the menopause.
Slovenian: Količina testosterona v krvi se po menopavzi zniža.
English: The CHMP noted that there was insufficient long-term data on the safety of the medicine in this larger group of patients and was therefore of the opinion that the medicine's benefits in these women did not outweigh its risks.
Slovenian: CHMP je menil, da ni zadostnih podatkov o dolgoročni varnosti zdravila pri tej večji skupini bolnic, in izrazil mnenje, da koristi zdravila pri teh ženskah ne odtehtajo njegovih tveganj.
English: The company presented results of four studies in a total of 2,245 women with HSDD.
Slovenian: Družba je predstavila rezultate štirih študij, v katerih je sodelovalo 2 245 žensk z motnjo hipoaktivne spolne želje.
English: The active substance in Intrinsa, testosterone, is a natural sex hormone produced in men and, to a lesser extent, in women.
Slovenian: Zdravilna učinkovina v zdravilu Intrinsa, testosteron, je naravni spolni hormon, ki ga proizvajajo moški in v manjši meri tudi ženske.
English: The patch releases 300 micrograms of the active substance testosterone over 24 hours.
Slovenian: Obliž v 24 urah sprosti 300 mikrogramov zdravilne učinkovine testosteron.
English: On 22 September 2010, Warner Chilcott Pharmaceuticals UK Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the marketing authorisation for Intrinsa, to extend treatment to all postmenopausal women with hypoactive sexual desire disorder.
Slovenian: Družba Warner Chilcott Pharmaceuticals UK Limited je dne 22. septembra 2010 uradno obvestila Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za spremembo dovoljenja za promet z zdravilom Intrinsa, namenjenim daljšemu zdravljenju žensk po menopavzi z motnjo hipoaktivne spolne želje.
English: The company informed the CHMP that there are no consequences for patients currently in clinical trials or compassionate use programmes with Intrinsa.
Slovenian: Družba je obvestila CHMP, da umik nima nobenih posledic za bolnice, ki trenutno sodelujejo v kliničnih preskušanjih ali programih sočutne uporabe zdravila Intrinsa.
English: They were given either Intrinsa or placebo (a dummy treatment).
Slovenian: Dajali so jim zdravilo Intrinsa ali placebo (zdravilo brez zdravilne učinkovine).
English: Intrinsa is a transdermal patch (a patch that delivers a medicine across the skin).
Slovenian: Zdravilo Intrinsa je transdermalni obliž (obliž, ki dovaja zdravilo skozi kožo).
English: It is already used to treat women with hypoactive sexual desire disorder (HSDD, a lack of sexual thoughts and sexual desire) who have had their womb and both ovaries surgically removed.
Slovenian: Uporablja se za zdravljenje žensk z motnjo hipoaktivne spolne želje (HSDD, pomanjkanje spolnih misli in spolnega poželenja), ki so jim kirurško odstranili maternico in oba jajčnika.
English: Low testosterone levels have been linked to low sexual desire and to reduced sexual thoughts and arousal.
Slovenian: Nizke ravni testosterona so povezane z majhnim spolnim poželenjem ter
English: Based on the review of the data and the company's response to the CHMP's lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Intrinsa could not have been approved for use in all postmenopausal women who have HSDD.
Slovenian: Na podlagi pregleda podatkov in odgovorov družbe na seznam vprašanj, ki jih je zastavil CHMP, je Odbor v času umika vloge izrazil določene zadržke in začasno menil, da zdravila Intrinsa ni mogoče odobriti za zdravljenje vseh žensk po menopavzi z motnjo hipoaktivne spolne želje.
English: In postmenopausal women, Intrinsa was expected to release testosterone through the skin into the bloodstream to produce testosterone levels that match the levels seen before the menopause.
Slovenian: Pri ženskah po menopavzi naj bi zdravilo Intrinsa sproščalo testosteron skozi kožo v krni obtok in tako zagotavljalo takšno raven testosterona, kot je bila prisotna pred menopavzo.
English: What is Intrinsa?
Slovenian: Kaj je zdravilo Intrinsa?
English: This was to incude all women who have been through the menopause and not only those who are ‘surgically postmenopausal' as result of having had their womb or ovaries removed.
Slovenian: To naj bi vključevalo vse ženske po menopavzi in ne le tistih, ki so v menopavzi zaradi kirurške odstranitve maternice ali jajčnikov.
English: What was Intrinsa expected to be used for?
Slovenian: Za kaj naj bi se zdravilo Intrinsa uporabljalo?
English: Some of the women had their womb and both ovaries surgically removed while others were postmenopausal women who had not had their womb or ovaries removed.
Slovenian: Nekaterim sodelujočim ženskam so kirurško odstranili maternico in oba jajčnika, druge ženske pa so bile po menopavzi, vendar jim maternice ali jajčnikov niso odstranili.
English: How is Intrinsa expected to work?
Slovenian: Kako naj bi zdravilo Intrinsa delovalo?
English: Intrinsa is expected to work in the same way as it does in women who have had their womb and both ovaries surgically removed.
Slovenian: Zdravilo Intrinsa naj bi delovalo na enak način kot pri ženskah, pri katerih so kirurško odstranili maternico in oba jajčnika.